# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $...
Piper Sandler analyst Yasmeen Rahimi upgrades Design Therapeutics (NASDAQ:DSGN) from Neutral to Overweight and raises the pr...
The Dow Jones index closed lower by over 150 points on Monday. When insiders purchase or sell shares, it indicates their confid...
RBC Capital analyst Leonid Timashev reiterates Design Therapeutics (NASDAQ:DSGN) with a Sector Perform and maintains $4 pric...
Wedbush analyst Laura Chico reiterates Design Therapeutics (NASDAQ:DSGN) with a Neutral and maintains $5 price target.
New Drug Product for Friedreich Ataxia (FA) DT-216P2 with Favorable Nonclinical Pharmacokinetic and Injection Site Safety Profi...
Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $...
Companies Reporting Before The Bell • Tencent Music Enter Gr (NYSE:TME) is projected to report quarterly earnings at $0.14 per...